Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
2142 articles with Johnson & Johnson Family of Companies
The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, N.J.
Johnson & Johnson will host a review of its Pharmaceutical businesses for the investment community beginning at 8:30 a.m. on Wednesday, May 15, 2019 at the Hyatt Regency Hotel in New Brunswick, New Jersey, and ending at approximately 2:30 p.m.
4/24/2019Life sciences giant blamed the Medicare "doughnut hole" and increased competition for the blood thinner's declining sales.
Johnson & Johnson Innovation Announces New Research That May Lead to Opportunities for Earlier Interception Strategies in Lung Cancer
First published data from research alliance with Boston University focuses on role of the immune system in the early development of lung cancer, opening a potential path to intercept the disease-causing process
Johnson & Johnson announced results for first-quarter 2019.
It should be no surprise that the Washington, DC and Baltimore areas are considered strong for life sciences. This is BioSpace’s BioCapital Community Hotbed.
Johnson & Johnson Innovation and Children's National Health System* to Launch JLABS @ Washington, DC at the new Children's National Research and Innovation Campus in 2020
The Biomedical Advanced Research and Development Authority (BARDA) collaborates with JLABS to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases with residency at JLABS @ Washington, DC
ViiV Healthcare, presented three-year data from the SWORD 1 and 2 clinical trials in HIV. The data was presented at the 25th Annual Conference of the British HIV Association (BHIVA) in Bournemouth, UK.
Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma
First DARZALEX combination treatment regimen being pursued in the frontline setting for transplant eligible patients with multiple myeloma
Both Bayer and J&J claim the lawsuits are without merit but believe that the $775 million settlement will allow the companies to move on from costly litigation.
In a filing with the U.S. Securities and Exchange Commission, Johnson & Johnson said it will abandon development of AL-8176, one of the assets it acquired in the Alios deal.
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, April 16th, to review first-quarter results.
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
With a major lawsuit in Oklahoma targeting Johnson & Johnson and Purdue Pharma’s involvement in the opioid epidemic starting in May, many of the legal documents are being released, with strategies and sometimes incendiary rhetoric coming to light.
Humira generated nearly $20 billion in revenue for the Illinois-based company. Celgene's Revlimid earned about half-as-much in 2018.
Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
Application supported by the Phase 3 MAIA study being reviewed under the FDA Real-Time Oncology Review pilot program
Often, patients prefer oral medications over receiving an injection or infusion, but daily pills sometimes result in compliance problems. In the case of this combination injection, it would, if approved, require patients to visit a clinic or physician once a month for the shot.
Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy
ATLAS and FLAIR studies presented at the 2019 Conference on Retroviruses and Opportunistic Infections met primary endpoints showing long-acting, injectable regimen to be effective in virally suppressed adults living with HIV
Houston based depression psychiatrist, Dr. Sandhya Prashad, M.D., tells how this new drug might save lives and cost less than expected
FDA approves Spravato, a version of ketamine backed by Johnson & Johnson that sees rapid results in patients battling treatment resistant depression and suicide
New Global Headquarters for Johnson & Johnson Human Performance Institute® Reimagines Workplace Wellbeing
Multi-sensory Experience Fuels Physical, Mental, Emotional and Spiritual Energy for Higher Performance and Purposeful Living